JNJ
Johnson & Johnson Health Care Pharmaceutical Preparations S&P 500Dow 30Russell 3000
$273.20Close
$852.3BMarket cap
$181.90 – $278.4352-week range
Mid-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Near its high 2% below its 52-week high
Cautions
- Earnings shrinking EPS −96% year on year
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
2%
1wk
up 3.6%
price change
1mo
up 3.2%
price change
12-month return
up 48%
market up 11% ·
its own up 39%
F-score
4 / 9
Weak
Altman Z
6.56
Low risk
P/E
31.8×
price / earnings
PEG
0.35
P/E / EPS growth
P/B
10.5×
price / book
Earnings yield
up 3.7%
EBIT / enterprise value
Cheaper than
36%
of the market · expensive
Revenue growth
up 6%
year on year
EPS growth
down 96%
latest quarter · -95 pts
Sales growth
up 6%
latest quarter · -1 pts
ROE
up 35%
return on equity
Free cash margin
up 21%
$19.7B FCF
D/E
0.48
long-term debt / equity
Net debt / EBITDA
0.5×
Interest cover
—EBIT / interest
Piotroski tests
- profits not fully backed by cash
- took on more long-term debt
- short-term liquidity weakened
- gross margin narrowed
- assets working less efficiently
- profitable on its assets
- generating cash from operations
- profitability improving
- no new shares issued
Trade setup
ATR%
2.5%
$6.71 a day · 2×ATR $259.78
RS
78 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.3×
vs 50-day average
Up/down volume
0.87
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Gross margin narrowing Gross margin fell from 69.1% to 67.9%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Oct 13, 2026
Results reaction
Oct 13, 2026-3% vs market2 sessions after results
Options
$13.3M25.4% IV · activity
Financials
- Gross 68%
- Net 28%
- Free cash 21%
- Cash
- Long-term debt
| FY2020Jan 3, 2021 | FY2021Jan 2, 2022 | FY2022Jan 1, 2023 | FY2023Dec 31, 2023 | FY2024Dec 29, 2024 | FY2025Dec 28, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $82.6B | $78.7B | $80.0B | $85.2B | $88.8B | $94.2B |
| Gross margin | 66% | 70% | 69% | 69% | 69% | 68% |
| Net income | $14.7B | $20.9B | $17.9B | $35.2B | $14.1B | $26.8B |
| Net margin | 18% | 27% | 22% | 41% | 16% | 28% |
| Earnings per share | $5.51 | $7.81 | $6.73 | $13.73 | $5.79 | $11.03 |
| Free cash flow | $20.2B | $19.8B | $17.2B | $18.2B | $19.8B | $19.7B |
| Free cash margin | 24% | 25% | 21% | 21% | 22% | 21% |
| Cash | $14.0B | $14.5B | $12.9B | $21.9B | $24.1B | $19.7B |
| Long-term debt | $32.6B | $30.0B | $26.9B | $25.9B | $30.7B | $39.4B |
| Shareholders' equity | $63.3B | $74.0B | $76.8B | $68.8B | $71.5B | $81.5B |
| Shares outstanding | 3.12bn | 3.12bn | 3.12bn | 3.12bn | 3.12bn | 3.12bn |
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $258 – $289 ±5.7% by Nov 27, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Smaller 25.4% priced · 31.3% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- About the same
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: no change
Positioning
- Premium traded
- $13.3M calls $9.7M · puts $3.7M · latest session
- 0.38× +0.07 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls -20.43k · puts -11.26k past week
For options traders: ATM IV 25.4% (-0.2% 1w) · 1m ÷ 3m IV 1.02 · 25Δ skew 0.4 pts · Net GEX $53.5M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 21, 2026 | Quarterly ↗ | Sep 27, 2026 | 24d |
| Jul 23, 2026 | Quarterly ↗ | Jun 28, 2026 | 25d |
| Apr 22, 2026 | Quarterly ↗ | Mar 29, 2026 | 24d |
| Feb 11, 2026 | Annual ↗ | Dec 28, 2025 | 45d |
| Oct 22, 2025 | Quarterly ↗ | Sep 28, 2025 | 24d |
| Jul 24, 2025 | Quarterly ↗ | Jun 29, 2025 | 25d |
| Apr 23, 2025 | Quarterly ↗ | Mar 30, 2025 | 24d |
| Feb 13, 2025 | Annual ↗ | Dec 29, 2024 | 46d |
| Oct 23, 2024 | Quarterly ↗ | Sep 29, 2024 | 24d |
| Jul 25, 2024 | Quarterly ↗ | Jun 30, 2024 | 25d |
| May 1, 2024 | Quarterly ↗ | Mar 31, 2024 | 31d |
| Feb 16, 2024 | Annual ↗ | Dec 31, 2023 | 47d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 13, 2026 | Results ↗ |
| Aug 4, 2026 | Director or officer change ↗ |
| Jul 29, 2026 | Regulation FD ↗ |
| Jul 28, 2026 | Regulation FD ↗ |
| Jul 15, 2026 | Results ↗ |
| Apr 28, 2026 | Shareholder vote ↗ |
| Apr 14, 2026 | Results · Other events ↗ |
| Jan 21, 2026 | Results ↗ |
| Oct 14, 2025 | Results · Other events ↗ |
| Sep 9, 2025 | Director or officer change ↗ |
| Jul 16, 2025 | Results ↗ |
| Jun 10, 2025 | Director or officer change ↗ |